You are here: Home » Companies » News
Business Standard

USFDA wraps up inspection of JB Chemicals Panoli unit with no observations

JB Chemicals & Pharmaceuticals said this facility has capacity of two billion tablets per annum, which is expandable to nine billion tablets per annum

Press Trust of India  |  New Delhi 

pharma, chemicals
Representative image

Wednesday said the US health regulator has concluded inspection of its manufacturing facility at Panoli in Gujarat without any observations.

The US Food and Drug Administration (USFDA) has concluded inspection of company's newly set-up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat, said in a BSE filing.

"At the end of inspection, no objectionable observations were found and hence no form 483 was issued," it stated.

The said inspection was carried out from June 24-28, 2019, the company said.

A Form 483, is issued by the USFDA to notify a company's management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.

said this facility has capacity of two billion tablets per annum, which is expandable to nine billion tablets per annum.

The company said new facility will augment its manufacturing capacity for regulated markets like the USA and the EU, as and when the product approvals are received.

Shares of JB Chemicals & Pharmaceuticals were trading 1.83 per cent lower at Rs 365.75 apiece on the BSE.

First Published: Wed, July 03 2019. 12:55 IST
RECOMMENDED FOR YOU